title: Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor.
abstract: Desloratadine (Clarinex), the major active metabolite of loratadine (Claritin), is a nonsedating antihistamine used for the treatment of seasonal allergies and hives. Previously we reported that the formation of 3-hydroxydesloratadine, the major human metabolite of desloratadine, involves three sequential reactions, namely N-glucuronidation by UGT2B10 followed by 3-hydroxylation by CYP2C8 followed by deconjugation (rapid, nonenzymatic hydrolysis of the N-glucuronide). In this study we assessed the perpetrator potential of desloratadine based on in vitro studies of its inhibitory effects on cytochrome P450 and UDP-glucuronosyltransferase (UGT) enzymes in human liver microsomes (HLM). Desloratadine (10 µM) caused no inhibition (<15%) of CYP1A2, CYP2C8, CYP2C9, or CYP2C19 and weak inhibition (32-48%) of CYP2B6, CYP2D6, and CYP3A4/5. In cryopreserved human hepatocytes (CHH), which can form the CYP2C8 substrate desloratadine N-glucuronide, desloratadine did not inhibit the CYP2C8-dependent metabolism of paclitaxel or amodiaquine. Assessment of UGT inhibition identified desloratadine as a potent and relatively selective competitive inhibitor of UGT2B10 (Ki value of 1.3 μM). Chemical inhibition of UGT enzymes in HLM demonstrated that nicotine (UGT2B10 inhibitor) but not hecogenin (UGT1A4 inhibitor) completely inhibited the conversion of desloratadine (1 µM) to 3-hydroxydesloratadine in HLM fortified with both NADPH and UDP-glucuronic acid. 3-Hydroxydesloratadine formation correlated well with levomedetomidine glucuronidation (UGT2B10 marker activity) with a panel of individual CHH (r(2) = 0.72). Overall, the results of this study confirm the role of UGT2B10 in 3-hydroxydesloratadine formation and identify desloratadine as a relatively selective in vitro inhibitor of UGT2B10.
authors.affiliation: XenoTech, LLC, Lenexa, Kansas (F.K., P.Y., J.E.B.) and XPD Consulting, Shawnee, Kansas (A.P).
authors.forename: Faraz
authors.initials: F
authors.lastname: Kazmi
authors.affiliation: XenoTech, LLC, Lenexa, Kansas (F.K., P.Y., J.E.B.) and XPD Consulting, Shawnee, Kansas (A.P).
authors.forename: Phyllis
authors.initials: P
authors.lastname: Yerino
authors.affiliation: XenoTech, LLC, Lenexa, Kansas (F.K., P.Y., J.E.B.) and XPD Consulting, Shawnee, Kansas (A.P).
authors.forename: Joanna E
authors.initials: JE
authors.lastname: Barbara
authors.affiliation: XenoTech, LLC, Lenexa, Kansas (F.K., P.Y., J.E.B.) and XPD Consulting, Shawnee, Kansas (A.P) aparkinson@xpd.us.com.
authors.forename: Andrew
authors.initials: A
authors.lastname: Parkinson
mesh_terms: D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology*; D014453:Glucuronosyltransferase / Q000037:antagonists & inhibitors*; D039563:Histamine H1 Antagonists, Non-Sedating / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D017336:Loratadine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology
chemical_list: D004791:Enzyme Inhibitors; D039563:Histamine H1 Antagonists, Non-Sedating; D017336:Loratadine; D003577:Cytochrome P-450 Enzyme System; C552162:UGT2B10 protein, human; D014453:Glucuronosyltransferase; C121345:desloratadine